Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Invitrogen™ VEGF-164 Polyclonal Antibody

Goat Polyclonal Antibody

Supplier:  Invitrogen™ PA547021

Catalog No. PIPA547021


Only null left
Add to Cart

Description

Description

In sandwich ELISAs, less than 0.04% cross-reactivity with recombinant human (rh) VEGF121, rhVEGF165, and rhVEGF/PlGF is observed. Reconstitute at 0.2 mg/mL in sterile PBS. Endoxin level is <0.10 EU per 1 μg of the antibody by the LAL method.

VEGF-164 is a gene target that encodes for the vascular endothelial growth factor. This protein is responsible for promoting angiogenesis. VEGF-164 has been shown to be involved in the development of various diseases, including cancer, cardiovascular disease, and diabetic retinopathy. Targeting this gene has become an important strategy in the development of new therapeutics for these conditions.
TRUSTED_SUSTAINABILITY
Specifications

Specifications

VEGF-164
Polyclonal
Unconjugated
VEGFA
Vascular Endothelial Growth Factor, Vascular Permeability Factor, VEGFA, VPF
Goat
Antigen affinity chromatography
RUO
22339
-20°C, Avoid Freeze/Thaw Cycles
Lyophilized
ELISA, Immunohistochemistry (Frozen), Neutralization, Western Blot
0.2 mg/mL
PBS with 5% trehalose and No Preservative
Q00731
VEGFA
Sf 21-derived recombinant mouse VEGF164 Ala27-Arg190.
100 μg
Primary
Mouse
Antibody
IgG
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Product Certifications
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.